Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)

Opioid-Related Disorders Clinical Trial

— MATICCE  

Official title:

Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01344122
• Other study ID #: CJDATS2-001
• Secondary ID: U01DA016191
• Status: Completed
• Phase: N/A
• First received: April 21, 2011
• Last updated: October 28, 2014
• Start date: October 2010
• Est. completion date: September 2013

Study information

• Verified date: October 2014
• Source: Rhode Island Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The goal of this study is to see whether or not a strategic planning process is able to introduce and sustain improvements in the working relationship between probation/parole departments and community-based addiction treatment agencies that provide medication assisted therapy (MAT) for individuals with opioid or alcohol dependence. In addition, this study seeks to improve probation/parole agency personnel's knowledge and perceptions about MAT, and increase the number of appropriate referrals to community treatment agencies that provide MAT. There are three phases to this study. Phase 1 includes a pilot study to determine the quality and availability of client level records and the collection of baseline data (the pilot study protocol was previously submitted to TMH IRB). Phase 2 will consist of a Knowledge, Perceptions and Information (KPI) intervention during which probation/parole agencies will undergo training to increase knowledge about the effectiveness of MAT, and complete a post training assessment to evaluate the effectiveness of the KPI intervention. During Phase 3, probation/parole agencies will be randomly assigned to a 12-month Organizational Linkage Intervention (OLI) condition or to control (no further intervention). Agencies assigned to the OLI will establish a Pharmacotherapy Exchange Council (PEC) that consists of staff from both the probation/parole and community treatment agencies. The PEC will undergo a strategic planning process to increase the availability of MAT for opiate and/or alcohol dependent individuals who are on probation/parole.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: September 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A and older
• Eligibility: Probation/parole or community treatment agency staff.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Alcohol-Related Disorders
• Disease
• Opioid-Related Disorders

Intervention

Other:
• KPI training only
See comparison arm description.
• KPI plus OLI
See experimental arm description.

Locations

Country	Name	City	State
n/a

Sponsors (12)

Lead Sponsor	Collaborator
Rhode Island Hospital	Arizona State University, Friends Research Institute, Inc., National Development and Research Institutes, Inc., National Institute on Drug Abuse (NIDA), Temple University, Texas Christian University, University of California, Los Angeles, University of Connecticut, University of Delaware, University of Kentucky, University of Puerto Rico

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Opinions About MAT	Measures knowledge, perceptions, and intentions regarding the use of pharmacotherapy for the treatment of opioid and alcohol dependence. Will be assessed at baseline, post-training, post intervention, and 6-month follow-up.	6-month follow-up	No
Secondary	Interorganizational Relationships	Will be assessed at baseline, and post intervention (6-month follow-up).	6-month follow-up	No
Secondary	Referrals to Medication Assisted Treatment (MAT)	Estimated numbers of alcohol- and opiate-dependent offenders on Probation/Parole	6-Month Follow-up	No